Everyone must be very curious about the multivalent dendritic cell vaccine. According to the information provided by the Tokyo Cancer Clinic (formerly: Abe Medical Oncology Clinic), they also provide the fifth generation of specific immune cell therapy, and also use non-specific Sexual NK cells together to increase the effect. The main mechanism of specific immunotherapy is that the dendritic cell vaccine is delivered to T cells through various characteristics on the surface of cancer cells, and then activated into killer T cells to attack cancer cells. However, cancer cells still evade this mechanism by hiding these features. Multivalent dendritic cell vaccine is the characteristic of true cancer cells. It is combined with more than four overlapping and long-chain peptides suitable for patients such as WT1, NY-ESO-1, MAGE-A3, etc. to create a multivalent tree Stem Cell Vaccine. Another characteristic is that these peptides have MHC class I and class II.

What is the difference between long-chain peptides? Long chains can prevent the competition between antigens. The 2010 Forum on Vaccine Science pointed out that the length of the peptide is quite important. If it is a short chain, it will be difficult to combine with the MHC class I of dendritic cells, resulting in the inability to fully activate the antigen prompts to T cells, and cannot fully attack cancer cells.

In addition to using a long-chain peptide with 13 amino acids, it also has the characteristics of overlapping. Therefore, according to Dr. Abe's theory, these peptides do not need to be matched with HLA (white blood cell type), and can also be applied to various cancer patients. At the same time, they can also activate helper T cells. The difference between chain peptides and short chains.

In order to distinguish it from other immunotherapies, Dr. Abe specially applied for patents in Japan and the United States, and named it ABeVax® (Anticancer Binary Epitope Vaccine), and will continue to challenge this field in the future.